Novel molecule could inform new therapies for stroke-related brain injury

FHS
July 10, 2024
7:34 pm

A newly developed molecule, LK-2, could inform new therapies for stroke-related brain injury, finds scientists at The Hospital for Sick Children (SickKids).

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the

October 27, 2024

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

April 19, 2024

Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer

A new research paper was published in Oncotarget’s Volume 15 on August 26, 2024, entitled, “Inhibition of miR-10b treats metastatic breast cancer by targeting stem

August 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.